傳統(tǒng)抗凝劑由于安全性等原因，在腦梗死的治療中受到較多限制。阿加曲班作為新型抗凝劑的典型代表之一，具有單靶點(diǎn)、半衰期短、量效穩(wěn)定等特點(diǎn)，從而全面提高了臨床抗凝的安全性。阿加曲班在腦梗死治療方面積累了大量的研究和證據(jù)，但尚缺乏系統(tǒng)的梳理。按照TOAST分型、OCSP分型以及不同的治療時(shí)機(jī)，對(duì)阿加曲班治療腦梗死的研究進(jìn)行分類(lèi)介紹，以期為腦梗死的抗凝治療和阿加曲班的臨床應(yīng)用提供更多依據(jù)和建議。

Traditional anticoagulants are limited in treatment of cerebral infarction due to safety reasons. As one of the typical representatives of the new anticoagulant, argatroban has the characteristics of single target, short half-life, and stable quantity, thus improving the safety of clinical anticoagulation comprehensively. Argatroban has accumulated a great deal of research and evidence in the treatment of cerebral infarction, but it lacks systematic combing. According to the TOAST classification, OCSP classification, and different treatment timing, the study on argatroban in treatment of cerebral infarction is discussed in this paper, in order to provide more evidence and suggestion for the anticoagulant therapy of cerebral infarction and the clinical application of argatroban.